Novartis launches "Meet The PROS" to raise awareness and support education for PIK3CA-Related Overgrowth Spectrum (PROS)
Retrieved on:
Tuesday, August 31, 2021
MCAP, PIK3CA, Student, Pandemic, Research, PIK3CA-related overgrowth spectrum, Awareness, Mutation, Safety, CLOVES syndrome, Disorder, FAO, Medicine, Blood, Shoe, U.S. Securities and Exchange Commission, FIL, Forward-looking statement, Child, Vincent Gigante, Clinical trial, Chronic pain, Sale, Degenerative disease, Pectus carinatum, Friends, Twitter, KTS, Diagnosis, Natural history, Government, Birth, ILM, Klippel–Trénaunay syndrome, Veni, vidi, vici, National, Novartis, Education, Face, Quality of life, Praeter legem, Speech, Vladimir Prosin, Regulation, HME, Physician, Pain, Private Securities Litigation Reform Act, Form 20-F, Anomaly, Marketing, Patient, Caregiver, Foundation for the National Institutes of Health, Classification, Parent, Medical device, Tourism, Residential care, Tutoring, Pharmaceutical industry
Through theMeet The PROSinitiative, we aim to answer the community's call for more awareness and educational resources," said Reshema Kemps-Polanco, Head of Novartis Oncology, US.
Key Points:
- Through theMeet The PROSinitiative, we aim to answer the community's call for more awareness and educational resources," said Reshema Kemps-Polanco, Head of Novartis Oncology, US.
- "I'm hopeful that these resources will help parents and families learn more, feel less alone and raise awareness about the physical and emotional impacts of these rare conditions."
- "It's great to have additional resources, created by and for the community, to help raise awareness and education about PROS."
- Located in East Hanover, NJ, Novartis Pharmaceuticals Corporation an affiliate of Novartis is reimagining medicine to improve and extend people's lives.